Taken together, these data provide evidence toward a striking molecular similarity between metastatic cholangiocarcinoma and KRAS wildtype mPDAC that is not shared with KRAS mutant mPDAC, while being observed in two orthogonal study cohorts of patient tumor samples. Here, KRAS is linked to neoplasm.